How this fits in

Newer long-acting insulins are not recommended for the treatment of patients with type 2 diabetes according to the Dutch guideline NHG-Standaard diabetes mellitus type 2. However, this study shows that approximately a quarter of all patients with type 2 diabetes prescribed intermediate or long-acting insulins received a prescription for one of the newer insulins. Large variation among general practices existed, even after correction for differences at the patient and practice level. This indicates opportunities for quality improvement of the pharmaceutical treatment of patients with type 2 diabetes.